Thermo Fisher rides Dx sales to Q2 revenue boost

Thermo Fisher Scientific ($TMO) beat analyst expectations in the second quarter, notching a 9% increase in revenue over the previous year despite declining net income.

The company's specialty diagnostics unit reported the largest growth, with sales jumping 28% to $732 million. Thermo Fisher's net income dropped 55% to $233.8 million, but that was expected by Thermo and Wall Street alike, after 2011's total was inflated by the company's selling off of business units.

Thermo posted adjusted profits of $1.22 per share, ahead of the $1.16 average analyst expectation, Reuters reports. The company lowered its 2012 revenue projection to between $12.1 billion and $12.3 billion, but raised its earnings estimate to between $4.74 and $4.84 a share.

While the company's diagnostics unit posted the highest growth, Thermo also reported an 8% sales boost in analytical technologies and a 2% rise in laboratory products. 

The company credits its jump in revenue and sales to the launch of new laboratory products and some strategic acquisitions. Thermo acquired chemicals producer Doe & Ingalls for $175 million in May, and, most recently, the company inked an agreement to purchase diagnostics firm One Lambda for $925 million.

- read Thermo's release
- get more from Reuters

Suggested Articles

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.